A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this Phase II study is to evaluate the progression-free survival at
6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated
with MEDI-575.